Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

Researchers have identified a gene therapy that could prevent life-threatening arrhythmias by restoring the heart’s ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

Vector-borne zoonotic diseases, transmitted by pathogens via arthropods like mosquitoes, ticks, and fleas, comprise 17% of the global infectious disease ...

The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...